Field Trip Health

Field Trip Health is a psychedelic-assisted therapy company headquartered in Toronto, Canada, that operates a growing network of clinics across North America delivering ketamine-assisted therapy to patients. The company pairs in-clinic treatment with proprietary digital tools designed to support patients through the preparation and integration phases of their therapeutic journey, creating a tech-enabled care model that extends beyond the treatment room. Their drug development subsidiary conducts psilocybin research aimed at advancing novel psychedelic compounds through clinical development. This combination of direct patient care and pharmaceutical research positions Field Trip as a vertically integrated player across both the clinical and scientific dimensions of the psychedelic medicine space.

Field Trip Health is publicly traded on the Canadian Securities Exchange, giving it access to capital markets at a relatively early stage of the emerging psychedelic therapy industry. The company has established a multi-city clinic footprint spanning major metropolitan areas across the United States and Canada, reflecting an aggressive expansion strategy during a period of rapid sector growth. Their proprietary digital platform, developed alongside their clinical operations, represents an attempt to standardize and scale the patient experience in a field where therapeutic protocols are still being defined. The psilocybin research arm further signals ambitions to participate in the next wave of regulatory approvals as substances beyond ketamine move closer to clinical acceptance.

Field Trip Health matters to the neurotech industry because it represents one of the clearest examples of how digital health infrastructure can be layered onto emerging neurological treatment modalities. By embedding technology into the psychedelic therapy workflow, the company is helping to establish data-driven standards for a therapeutic category that has historically resisted systematization. Their model demonstrates that psychedelic medicine can be approached with the operational rigor and scalability expectations that institutional investors and healthcare systems require. As regulatory pathways for psychedelic therapies continue to evolve, companies like Field Trip that combine clinical delivery with proprietary technology and drug development pipelines will likely serve as blueprints for the broader industry.